drugset / Trial / NCT00438789

The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol

NCT00438789

Expanded access Approved for marketing Alexion Pharmaceuticals, Inc.

Summary

The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Eculizumab Monoclonal antibody 600 mg Intravenous
Subject Eculizumab Monoclonal antibody 900 mg Intravenous